CCL2 and neoplasm: In contrast, the combination of C‐C motif chemokine ligand 2 (CCL2) and interferon gamma (IFN‐g) can drive an anti‐tumour phenotype in PDAC myeloid cells, and this is particularly important in the presence of CD40 agonist treatment.95